RFG has a keen appetite for Life Science opportunities due to the substantial experience Mr. Womack gained in organizing and investing in medical device companies.
ARTELLA Solutions, Inc. www.artellainc.com
ARTELLA Solutions, Inc. is an Independent Diagnostic Testing Facility (IDTF) that deploys wireless Mobile Cardiac Telemetry (MCT) patches that replaces a traditional, cumbersome Holter monitor with an unobtrusive, wearable patch that provides real-time monitoring of cardiac events and reports results under its proprietary back-end Reporting Engine. ARTELLA provides services to physicians, healthcare systems, and other IDTFs.
Liprostin Group www.liprostingroup.com
Liprostin Group has a COVID-19 treatment that mitigates deadly cytokine storms triggered by runaway inflammation. Additionally, there is an excellent opportunity to conduct pivotal clinical trials for Peripheral Artery Disease (PAD) for commercialization.
Our licensed US patent covers encapsulation of prostaglandin E-1 (PGE-1), also known as Alprostadil, a generic drug, within a multilamellar liposome creating a platform for development and treatment of vascular diseases such as COVID-19, Peripheral Artery Disease (PAD), Acute Respiratory Disease Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Asthma and Pneumonia.
Monebo Technologies, Inc. www.monebo.com
Monebo Technologies, Inc. designs, develops, and licenses complex ECG algorithms to medical device developers, monitoring centers, system integrators and others for use in a variety of monitoring applications. Monebo works closely with their customers, such as ARTELLA, to develop and produce ECG analysis algorithms specific to their applications and requirements. Located in Austin, TX, Monebo was one of the initial companies to receive a direct investment from the State of Texas Enterprise fund in 2005. Mr. Womack has been a member of their Board of Directors since that time when he participated in their initial seed stock offering.
AMBROSE Cell Therapy www.ambrosecelltherapy.com
AMBROSE Cell Therapy was founded in 2018 by Matthew (Matt) Feshbach with the Mission: To help people with chronic degenerative diseases improve symptoms, function, and quality of life using adult stem cell therapy. To accomplish this, AMBROSE accesses the mixed population of stem and regenerative cells in a patient’s fat (adipose tissue). This cell preparation, when clinical grade, is called adipose-derived stem and regenerative cells (ADRCs).
In 2019, the passage of the Right to Try Act dovetailed with the technologies, protocols, and patient criteria that Matt believed would best address the unmet need of no-option patients. AMBROSE Cell Therapy procedures are performed by board-certified specialist physicians who provide our cell therapy services at licensed, Joint Commission Accredited (JACO) facilities in Tampa, FL and Beverly Hills, CA. Mr. Womack was a founding investor in AMBROSE and serves on its Board of Directors.